Polyethylene modified adenosine deaminase

Hershfield, M.S., R.H. Buckley, M.L. Greenberg, A.L. Melton, R. Schiff) C. Hatem, J. Kurtzberg, M.L. Markert, R.H. Kobayashi, A.L. Kobayashi, et al., Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med, 1987. 316(10) 589-96. 

T-lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. Weinberg, K., Hershfield, M.S., Bastian, J., Kohn, D., Sender, L., Parkman, R., Lenarsky, C. (1993).JClin Invest, 2 596-602. 

Levy, Y., Hershfield, M. S., Fernandez-Mejia, C., et al. Adenosine deaminase deficiency with late onset of recurrent infections Response to treatment with polyethylene glycol-modified adenosine deaminase. J. Pediatr. 113(2) 312-317. 1988. 

Hershfield M S, et al (1987). Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. New Eng. J. Med. 316(10) 589-596. 

Chaffee S, Mary A, Stiehm E R, et al. (1992). IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. /. Clin. Invest. 89 1643-1651. 

Acid-catalyzed matrices, kinetics of controlled release, 170-179 Active targeting, definition, 276 Adenosine deaminase, activity of polyethylene glycol modified enzymes, 98-99 Adjuvax... 

Polyethylene glycol) (PEG) molecules attached to adenosine deaminase (ADA) have been used in patients exhibiting symptoms of the severe combined immunodeficiency syndrome (SCID) caused by ADA deficiency. The modified enzyme has a plasma half-life of weeks as compared to the unmodified enzyme (minutes) (248). PEG-L-asparaginase has induced remissions in patients with non-Hodgkin s lymphoma (248). However, one disadvantage of PEG-enzyme treatment is its expense, ie, a year s treatment costs about 60,000 (248). 

---